These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17121428)

  • 1. The CADEUS study: methods and logistics.
    Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Blin P; Moore N;
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):571-80. PubMed ID: 17121428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
    Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prescriber nonresponse on patient representativeness.
    Fourrier-Réglat A; Droz-Perroteau C; Bénichou J; Depont F; Amouretti M; Bégaud B; Moride Y; Blin P; Moore N;
    Epidemiology; 2008 Mar; 19(2):186-90. PubMed ID: 18300697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort.
    Fourrier-Réglat A; Cuong HM; Lassalle R; Depont F; Robinson P; Droz-Perroteau C; Pariente A; Bégaud B; Blin P; Moore N
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):474-81. PubMed ID: 20437457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study.
    Fourrier-Réglat A; Lacoin L; Pariente A; Lassalle R; Robinson P; Droz-Perroteau C; Bégaud B; Blin P; Moore ND
    Clin Pharmacol Ther; 2010 Nov; 88(5):668-75. PubMed ID: 20861835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
    Schneeweiss S; Glynn RJ; Avorn J; Solomon DH
    J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis.
    Bernard MA; Bénichou J; Blin P; Weill A; Bégaud B; Abouelfath A; Moore N; Fourrier-Réglat A;
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):573-83. PubMed ID: 22337160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX; Lee KY; Bertram CT; Goldstein JL
    Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.
    Fosbøl EL; Gislason GH; Jacobsen S; Abildstrom SZ; Hansen ML; Schramm TK; Folke F; Sørensen R; Rasmussen JN; Køber L; Madsen M; Torp-Pedersen C
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):822-33. PubMed ID: 18383428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E; Nedjar H; Bizzi A; Morin S
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
    J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    van der Veen WJ; van der Werf GT
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.